Accelerated tumor progression in mice lacking the ATP receptor P2X7.

The ATP receptor P2X7 (P2X7R or P2RX7) has a key role in inflammation and immunity, but its possible roles in cancer are not firmly established. In the present study, we investigated the effect of host genetic deletion of P2X7R in the mouse on the growth of B16 melanoma or CT26 colon carcinoma cells. Tumor size and metastatic dissemination were assessed by in vivo calliper and luciferase luminescence emission measurements along with postmortem examination. In P2X7R-deficient mice, tumor growth and metastatic spreading were accelerated strongly, compared with wild-type (wt) mice. Intratumoral IL-1β and VEGF release were drastically reduced, and inflammatory cell infiltration was abrogated nearly completely. Similarly, tumor growth was also greatly accelerated in wt chimeric mice implanted with P2X7R-deficient bone marrow cells, defining hematopoietic cells as a sufficient site of P2X7R action. Finally, dendritic cells from P2X7R-deficient mice were unresponsive to stimulation with tumor cells, and chemotaxis of P2X7R-less cells was impaired. Overall, our results showed that host P2X7R expression was critical to support an antitumor immune response, and to restrict tumor growth and metastatic diffusion.

[1]  M. Wallace,et al.  Abstract 2957: Investigating methyl-CpG DNA recognition in cancer , 2015 .

[2]  F. Wiklund,et al.  Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. , 2014, Carcinogenesis.

[3]  J. Köhl,et al.  C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. , 2013, Blood.

[4]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[5]  F. Di Virgilio,et al.  Purinergic signalling and cancer , 2013, Purinergic Signalling.

[6]  F. Di Virgilio,et al.  Detecting adenosine triphosphate in the pericellular space , 2013, Interface Focus.

[7]  C. Ricordi,et al.  Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7 , 2013, Circulation.

[8]  C. Ricordi,et al.  Effect of the Purinergic Inhibitor Oxidized ATP in a Model of Islet Allograft Rejection , 2013, Diabetes.

[9]  F. Di Virgilio,et al.  Purines, purinergic receptors, and cancer. , 2012, Cancer research.

[10]  F. Di Virgilio,et al.  P2 receptors and immunity , 2012, Microbes and infection.

[11]  I. Chessell,et al.  Genetic Background Strongly Influences the Bone Phenotype of P2X7 Receptor Knockout Mice , 2012, Journal of osteoporosis.

[12]  F. Di Virgilio,et al.  P2X7 receptor‐stimulation causes fever via PGE2 and IL‐1β release , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  F. Di Virgilio,et al.  Expression of P2X7 receptor increases in vivo tumor growth. , 2012, Cancer research.

[14]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[15]  F. Di Virgilio,et al.  The P2X7 Receptor and Pannexin-1 Are Both Required for the Promotion of Multinucleated Macrophages by the Inflammatory Cytokine GM-CSF , 2011, Journal of Immunology.

[16]  M. Bours,et al.  P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation. , 2011, Frontiers in bioscience.

[17]  C. Dinarello A clinical perspective of IL‐1β as the gatekeeper of inflammation , 2011, European journal of immunology.

[18]  W. Junger,et al.  Immune cell regulation by autocrine purinergic signalling , 2011, Nature Reviews Immunology.

[19]  M. Idzko,et al.  Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R , 2010, Nature Medicine.

[20]  F. Di Virgilio,et al.  Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  M. Gavala,et al.  Extracellular ATP May Contribute to Tissue Repair by Rapidly Stimulating Purinergic Receptor X7-Dependent Vascular Endothelial Growth Factor Release from Primary Human Monocytes , 2010, The Journal of Immunology.

[22]  L. Zitvogel,et al.  Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. , 2010, Cancer research.

[23]  C. Reid,et al.  The P2X7 Receptor Drives Microglial Activation and Proliferation: A Trophic Role for P2X7R Pore , 2009, The Journal of Neuroscience.

[24]  D. Ojcius,et al.  The P2X7 receptor and intracellular pathogens: a continuing struggle , 2009, Purinergic Signalling.

[25]  J. Lucas,et al.  Inhibition of the ATP-gated P2X7 receptor promotes axonal growth and branching in cultured hippocampal neurons , 2008, Journal of Cell Science.

[26]  F. Di Virgilio,et al.  Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase , 2008, PloS one.

[27]  Geoffrey Burnstock,et al.  Physiology and pathophysiology of purinergic neurotransmission. , 2007, Physiological reviews.

[28]  D. Ribatti,et al.  Endogenous IL-12 triggers an antiangiogenic program in melanoma cells , 2007, Proceedings of the National Academy of Sciences.

[29]  F. Di Virgilio,et al.  A role for P2X7 in microglial proliferation , 2006, Journal of neurochemistry.

[30]  J. Wiley,et al.  Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. , 2006, Blood.

[31]  F. Di Virgilio,et al.  Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. , 2005, Molecular biology of the cell.

[32]  M. Colombo,et al.  Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.

[33]  M. Seman,et al.  Cutting Edge: A Natural P451L Mutation in the Cytoplasmic Domain Impairs the Function of the Mouse P2X7 Receptor1 , 2002, The Journal of Immunology.

[34]  C. Gabel,et al.  Absence of the P2X7 Receptor Alters Leukocyte Function and Attenuates an Inflammatory Response , 2002, The Journal of Immunology.

[35]  R. North Molecular physiology of P2X receptors. , 2002, Physiological reviews.

[36]  I. N. Brown,et al.  Changes in murine bone marrow macrophages and erythroid burst‐forming cells following the intravenous injection of liposome‐encapsulated dichloromethylene diphosphonate (Cl2MDP) , 2001, European journal of haematology.

[37]  F. Virgilio Dr. Jekyll/Mr. Hyde : the dual role of extracellular ATP , 2000 .

[38]  M. Salgaller American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[39]  F. Di Virgilio,et al.  Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. , 1999, Journal of immunology.

[40]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[41]  F. Di Virgilio,et al.  Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. , 1997, Journal of immunology.

[42]  F. Di Virgilio,et al.  Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. , 1996, Journal of immunology.

[43]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[44]  T. Forrester An estimate of adenosine triphosphate release into the venous effluent from exercising human forearm muscle , 1972, The Journal of physiology.

[45]  M. Fujita,et al.  Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. , 2012, Cancer letters.

[46]  M. Bours,et al.  Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. , 2006, Pharmacology & therapeutics.

[47]  M. Remberger,et al.  Myeloablative and immunosuppressive properties of treosulfan in mice. , 2006, Experimental hematology.

[48]  F. Di Virgilio,et al.  Dr. Jekyll/Mr. Hyde: the dual role of extracellular ATP. , 2000, Journal of the autonomic nervous system.

[49]  F. Di Virgilio The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. , 1995, Immunology today.